Vensica is a pioneering company in the field of therapeutic ultrasound and drug delivery, focusing on the urinary bladder. The company leverages the known properties of ultrasound to increase tissue permeability and improve drug uptake. Vensica's core product is a drug delivery platform that uses ultrasound cavitation to safely and effectively deliver Botulinum Toxin A into the bladder wall. This procedure is quick, pain-free, and needle-free, performed in an office setting with minimal expected side effects.

Vensica primarily serves patients suffering from overactive bladder (OAB) and bladder cancer, tapping into a market opportunity exceeding $2 billion annually in the U.S. The business model revolves around the development and commercialization of its proprietary drug delivery platform, generating revenue through product sales and potentially licensing agreements.

Keywords: ultrasound, drug delivery, urinary bladder, Botulinum Toxin A, overactive bladder, bladder cancer, needle-free, pain-free, medical device, therapeutic technology.